Asensus Surgical Inc. (ASXC): Why You Should Keep An Eye On It

The stock of Asensus Surgical Inc. (AMEX:ASXC) increased by $0.01 on Tuesday to at $0.29, up 2.68 percent. The last five days have seen an average of 1,150,244 shares of common stock traded. 12 times new highs were reached in the current year, with a fall of -$0.0584. The average number of shares traded over the last 20 days was 1,566,286, while the average volume over the last 50 days totaled 1,834,236.

ASXC stock dropped -21.56% since last month. On 08/22/23, the company’s shares reached a one-month low of $0.2699. The stock touched a high of $1.18 on 02/21/23, after rallying from a low of $0.27 in 52 weeks. The price of ASXC stock has declined by -17.17% or -$0.0584 this year, reaching a new high 12 times. Still, the stock price is down -75.64% from the 52-week high.

Top 5 AI Stocks to Buy for 2023

The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything. According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.

Click Here to Download the FREE Report.

Sponsored

Insider Transactions

ASXC stock investors should be aware that Asensus Surgical Inc. (ASXC) stock had its last reported insider trading activity 179 days ago on Mar 03. On Mar 03, Director Biffi Andrea acquired 293,077 shares at $0.71 each. This transaction resulted in the insider spending $207,557.

Valuation Metrics

Beta for the stock is 1.65. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 10.67, the price-to-book (PB) ratio of 1.11.

Financial Health

For the three months ended June 29, Asensus Surgical Inc.’s quick ratio was 4.30, while its current ratio was 5.20, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is -79.60% percent. Based on annual data, it had gross profit of -$3.79 million and revenue of $7.09 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ASXC’s return on assets (ROA) during the last 12 months has been -76.00%. There was a -76.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -90.10%.

Earnings Surprise

According to Asensus Surgical Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.01 million, while revenues rose by 1.98% to $0.98 million. It was predicted that Asensus Surgical Inc.’s quarterly earnings would be -$0.09, but it ended up being -$0.08, beating the consensus by -12.50%. EBITDA was -$20.12 million for the quarter. At the end of Asensus Surgical Inc.’s most recent quarter ended June 29, its liabilities totaled 16.87 million, while its total debt was $5.48 million. Equity owned by shareholders amounts to $263.88 million.

Technical Picture

Here’s a quick look at Asensus Surgical Inc.’s (ASXC) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 37.30%, suggesting the stock is Neutral, with a 58.23% historical volatility rate.

The stochastic %K and %D were 14.51% and 14.25% respectively, while the average true range (ATR) was 0.0309. Based on the 14-day stochastic reading of 19.96%, the RSI (14) reading is 35.29%. On the 9-day MACD Oscillator, the stock is at -0.0006, and the 14-day reading is at -0.0124.

Analyst Ratings

In its analyst report released on September 08, 2022, Cantor Fitzgerald began covering Asensus Surgical Inc. (AMEX: ASXC). The stock was rated as an Overweight by the brokerage firm. Analysts have assigned Asensus Surgical Inc. (ASXC) an Buy rating. ASXC is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 2 others recommend it as a buy.

What is ASXC’s price target for the next 12 months?

The current consensus forecast for the stock is between $1.00 and $2.00, with a median target price of $1.50. In analyzing these forecasts, the average price target given by analysts for Asensus Surgical Inc. (ASXC) is $1.50.

Most Popular

Related Posts